ESC Premium Access

The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure

Congress Session

About the speaker

Professor John J V McMurray

Western Infirmary, Glasgow (United Kingdom of Great Britain & Northern Ireland)
82 presentations
2 followers

187 more presentations in this session

CHA2DS2-VASc score as independent outcome predictor in patients with acute ischemic stroke with and without atrial fibrillation

Speaker: Doctor C. Su (Taichung, TW)

Thumbnail

Type and severity of migraine determines long-term risk of atrial fibrillation in women: a nationwide population-based study

Speaker: Doctor T. Rhee (Seoul, KR)

Thumbnail

Association between renal function and clinical outcomes in elderly patients with nonvalvular atrial fibrillation: sub-analysis of the ANAFIE Registry

Speaker: Professor W. Shimizu (Tokyo, JP)

Thumbnail

The impact of maternal hypothyroidism on the prevalence of preeclampsia in a contemporary nationwide cohort.

Speaker: Doctor S. Alampoondi Venkataramanan (Worcester, US)

Thumbnail

Increased prevalence of premature coronary atherosclerosis after preeclampsia

Speaker: Doctor M. Hauge (Copenhagen, DK)

Thumbnail

Access the full session

Cardiovascular Disease in Special Populations ePosters

Speakers: Professor J. McMurray, Doctor C. Su, Doctor T. Rhee, Professor W. Shimizu, Doctor S. Alampoondi Venkataramanan...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

This platform is supported by

logo Novo Nordisk